Market Overview:
The global cancer drug market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising awareness about cancer and its treatment options, and technological advancements in the field of oncology. The global cancer drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into small molecule drugs and biologics. Small molecule drugs are further sub-segmented into traditional chemotherapies and targeted therapies. Biologics are further sub-segmented into monoclonal antibodies (mAbs) and therapeutic proteins/peptides. On the basis of application, the market is segmented into ovarian cancer, breast cancer, colorectal cancer, lungcancer,, prostatecancer,, pancreaticcancer,, leukemia&lymphomaand other cancers).
Product Definition:
PARP inhibitors are a class of cancer drugs that block the PARP enzyme. This enzyme helps repair DNA damage, so by blocking it, PARP inhibitors can kill tumor cells. They are used to treat certain types of cancer, including ovarian and breast cancers.
Lynparza:
Lynparza is a member of the class of drugs known as parp inhibitors. It works by blocking the action of PARP (poly ADP ribose polymerase) enzyme, which is responsible for making DNA repairs in cells damaged by cancerous mutations. The drug has been approved for use in patients with advanced ovarian cancer and non-small cell lung cancer (NSCLC).
Zejula:
Zejula is a drug that is approved to treat advanced ovarian cancer. It works by blocking the action of an enzyme called PARP (polymerase chain reaction). The drug has been found to extend survival in patients with ovarian cancer, and it can be used in combination with other drugs.
It was granted fast track designation for its faster than expected safety and efficacy results from the FDA as well as an orphan drug status from EMA.
Application Insights:
Breast cancer dominated the market for cancer drugs based on PARP inhibitor with a share of 21.1% in 2017 owing to the increasing number of breast tumor cases globally. Moreover, growing awareness about early diagnosis and treatment of breast cancer is expected to boost growth during the forecast period.
Ovarian cancer held a significant share in 2017 due to rising incidence rates and awareness regarding early detection among women aged 45 years and above. According to data published by Ovarian Cancer Canada, around 5-10% of women develop invasive ovarian tumors during their lifetime; however, only 1-2% experience these symptoms in their mid thirties or late twenties which indicates that most women will never know they have this disease until it is too late. This situation demands effective screening methods which can be used across various age groups thus driving demand for such drugs over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. Key factors contributing to its growth include a rise in awareness about early diagnosis, availability of effective treatment options, and presence of well-established healthcare facilities in this region. Moreover, high prevalence of cancer types such as ovarian and breast cancer is expected to drive the regional market during the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to increasing number of drug approvals by regulatory agencies for treating various cancers including ovarian, breast, liver & pancreas among others. In addition Rubraca was approved by FDA for use against ovarian cancer which has strong potential for driving this regional market during the forecast period (2018 - 2030). Lynparza was also approved by FDA for use against advanced prostate cancer which has strong potential for driving this regional market during the forecast period (2018 - 2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the PARP inhibitor market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and this number is expected to rise in future. This will create a high demand for PARP inhibitors and drive the growth of this market.
- Growing awareness about personalized medicine: There is an increasing trend towards personalized medicine across the globe due to its benefits such as improved patient outcomes and reduced healthcare costs. Personalized medicine involves using information about a patient’s genes or proteins to select treatments that are most likely to work well for that individual patient. PARP inhibitors are increasingly being used as targeted therapies due to their ability to specifically block tumor cells with defects in DNA repair pathways, making them ideal candidates for personalized medicine approaches. This growing awareness about personalized medicines will fuel the growth of the PARP inhibitor market in future years..
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Drug based on PARP Inhibitor Market Research Report
By Type
Lynparza, Zejula, Rubraca, Talzenna
By Application
Ovarian Cancer, Breast Cancer, Other
By Companies
AstraZeneca, Merck & Co, GSK, Clovis Oncology, Pfizer, Zai Lab
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
198
Number of Tables & Figures
139
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Drug based on PARP Inhibitor Market Report Segments:
The global Cancer Drug based on PARP Inhibitor market is segmented on the basis of:
Types
Lynparza, Zejula, Rubraca, Talzenna
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ovarian Cancer, Breast Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Merck & Co
- GSK
- Clovis Oncology
- Pfizer
- Zai Lab
Highlights of The Cancer Drug based on PARP Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lynparza
- Zejula
- Rubraca
- Talzenna
- By Application:
- Ovarian Cancer
- Breast Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Drug based on PARP Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer drug based on PARP inhibitor is a type of cancer medication that inhibits the activity of the protein kinase B (PARP) enzyme. This class of drugs is often used to treat various types of cancers, including breast cancer, prostate cancer, and lung cancer.
Some of the major companies in the cancer drug based on parp inhibitor market are AstraZeneca, Merck & Co, GSK, Clovis Oncology, Pfizer, Zai Lab.
The cancer drug based on parp inhibitor market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer Drug based on PARP Inhibitor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer Drug based on PARP Inhibitor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer Drug based on PARP Inhibitor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer Drug based on PARP Inhibitor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer Drug based on PARP Inhibitor Market Size & Forecast, 2018-2028
4.5.1 Cancer Drug based on PARP Inhibitor Market Size and Y-o-Y Growth
4.5.2 Cancer Drug based on PARP Inhibitor Market Absolute $ Opportunity
Chapter 5 Global Cancer Drug based on PARP Inhibitor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cancer Drug based on PARP Inhibitor Market Size Forecast by Type
5.2.1 Lynparza
5.2.2 Zejula
5.2.3 Rubraca
5.2.4 Talzenna
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cancer Drug based on PARP Inhibitor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cancer Drug based on PARP Inhibitor Market Size Forecast by Applications
6.2.1 Ovarian Cancer
6.2.2 Breast Cancer
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer Drug based on PARP Inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer Drug based on PARP Inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cancer Drug based on PARP Inhibitor Analysis and Forecast
9.1 Introduction
9.2 North America Cancer Drug based on PARP Inhibitor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cancer Drug based on PARP Inhibitor Market Size Forecast by Type
9.6.1 Lynparza
9.6.2 Zejula
9.6.3 Rubraca
9.6.4 Talzenna
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cancer Drug based on PARP Inhibitor Market Size Forecast by Applications
9.10.1 Ovarian Cancer
9.10.2 Breast Cancer
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cancer Drug based on PARP Inhibitor Analysis and Forecast
10.1 Introduction
10.2 Europe Cancer Drug based on PARP Inhibitor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cancer Drug based on PARP Inhibitor Market Size Forecast by Type
10.6.1 Lynparza
10.6.2 Zejula
10.6.3 Rubraca
10.6.4 Talzenna
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cancer Drug based on PARP Inhibitor Market Size Forecast by Applications
10.10.1 Ovarian Cancer
10.10.2 Breast Cancer
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cancer Drug based on PARP Inhibitor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size Forecast by Type
11.6.1 Lynparza
11.6.2 Zejula
11.6.3 Rubraca
11.6.4 Talzenna
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size Forecast by Applications
11.10.1 Ovarian Cancer
11.10.2 Breast Cancer
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cancer Drug based on PARP Inhibitor Analysis and Forecast
12.1 Introduction
12.2 Latin America Cancer Drug based on PARP Inhibitor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cancer Drug based on PARP Inhibitor Market Size Forecast by Type
12.6.1 Lynparza
12.6.2 Zejula
12.6.3 Rubraca
12.6.4 Talzenna
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cancer Drug based on PARP Inhibitor Market Size Forecast by Applications
12.10.1 Ovarian Cancer
12.10.2 Breast Cancer
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cancer Drug based on PARP Inhibitor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cancer Drug based on PARP Inhibitor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cancer Drug based on PARP Inhibitor Market Size Forecast by Type
13.6.1 Lynparza
13.6.2 Zejula
13.6.3 Rubraca
13.6.4 Talzenna
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cancer Drug based on PARP Inhibitor Market Size Forecast by Applications
13.10.1 Ovarian Cancer
13.10.2 Breast Cancer
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer Drug based on PARP Inhibitor Market: Competitive Dashboard
14.2 Global Cancer Drug based on PARP Inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Merck & Co
14.3.3 GSK
14.3.4 Clovis Oncology
14.3.5 Pfizer
14.3.6 Zai Lab
